XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) discloses in its largest-ever SEC filing that Nasdaq Chief Legal Officer Sarah Brooks has approved a conditional extension for continued listing.
On May 4, a Nasdaq hearing panel granted the company an exception for ongoing listing under specific conditions.
Public Shell Classification
Nasdaq officials classify XTL Biopharmaceuticals as a “public shell” under Listing Rule 5101. This determination deems current continued listing inappropriate.
Strict Compliance Conditions
The panel sets clear requirements: XTL must finalize its acquisition of Psyga Bio Ltd. and prove full compliance with all listing standards by June 30, 2026.
The company executes a stock purchase agreement for Psyga Bio, awaiting shareholder approval. Completion follows approval, expected no later than June 29, 2026.
XTL secures shareholder commitments up to $1.5 million to fund the deal. These funds return if the acquisition fails.
Monitoring Major Events
During the exception period, Nasdaq demands oversight of significant developments that could affect compliance. The company must report these comprehensively.
The panel requires reassessment of scenarios where listing may remain unsuitable. It reserves the right to seek more details before reinstating compliance.
Prior Rule Violation
XTL previously breached Nasdaq Listing Rule 5550(a)(2), tied to minimum bid price standards.
The firm targets a closing bid price over $1 after wrapping up equity analysis near March 25, 2026.
Pipeline Focus via Acquisition
Finalizing the Psyga Bio deal positions XTL to prioritize pipeline advancement and achieve structural listing compliance.
Details derive directly from the SEC submission.
